Rezafungin

Rezafungin
Names
Trade namesRezzayo
Other namesBiafungin; CD101
Clinical data
Drug classEchinocandin[1]
Main usesInvasive candidiasis[1]
Side effectsLow potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, infusion reaction, sun sensitivity, liver problems[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Legal
License data
Chemical and physical data
FormulaC63H85N8O17+
Molar mass1226.4 g/mol

Rezafungin, sold under the brand name Rezzayo, is an antifungal medication used to treat invasive candidiasis, including candidemia.[1] Specifically it is used in adults with few or no alternative treatment options.[1][2] It is given by slow injection into a vein.[1]

Common side effects include low potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, and constipation.[1] Other side effects may include infusion reactions, sun sensitivity, and liver problems.[1] Safety in pregnancy is unclear.[1] It is in the echinocandin class of medication.[1][3]

Rezafungin was approved for medical use in the United States in 2023.[1] It is expected to become available in the United States in the summer of 2023 and to be expensive.[4] It received an orphan medication designation in Europe in 2021.[5]

Medical uses

Dosage

It is given at an initial dose of 400 mg, which is followed by 200 mg once per week for three more weeks.[1]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 "DailyMed - REZZAYO- rezafungin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 2 July 2023. Retrieved 21 June 2023.
  2. ↑ "Rezzayo approved by FDA amid rapid Candida auris spread". thepharmaletter.com. March 23, 2023. Archived from the original on July 1, 2023. Retrieved April 4, 2023.
  3. ↑ Zhao Y, Perlin DS (September 2020). "Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data". Journal of Fungi. 6 (4): 192. doi:10.3390/jof6040192. PMC 7712954. PMID 32998224.
  4. ↑ "Rezafungin (Rezzayo)". IDStewardship. 23 March 2023. Archived from the original on 12 May 2023. Retrieved 21 June 2023.
  5. ↑ "EU/3/20/2385". European Medicines Agency. 18 May 2021. Archived from the original on 1 April 2023. Retrieved 22 June 2023.
Identifiers:
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.